DrugBiological
Ianalumab clinical trials
Also written VAY736.
Keep track of what changes. Save the ianalumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
32 studies that test it; most in 2023 (6); 1 more planned to start later
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 1 |
| 2022 | 5 |
| 2023 | 6 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 33 · Other 0
Often tested with
Tested in the same studies.
Iscalimab (2) · LYS-006 (1) · Arumakimig (1) · Remibrutinib (1) · Eltrombopag (1) · Thrombopoietin Receptor Agonist (1) · Ibrutinib (1)
Studies
Open first, then newest update. How each study uses ianalumab is read from its arms, and is right about nine times in ten.
Testing it · 33
- A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)RecruitingPhase 2Novartis PharmaceuticalsNCT07421167Written as ianalumab
- Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).RecruitingPhase 3Novartis PharmaceuticalsNCT06133972Written as Ianalumab
- Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)RecruitingPhase 3Novartis PharmaceuticalsNCT06711887Written as Ianalumab
- Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom BurdenRecruitingPhase 3Novartis PharmaceuticalsNCT07621809Written as VAY736
- A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.Not yet recruitingPhase 2Novartis PharmaceuticalsNCT07660172Written as Ianalumab
- A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of TherapiesActive, not recruitingPhase 2Novartis PharmaceuticalsNCT05885555Written as Ianalumab
- Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis SuppurativaCompletedPhase 2Novartis PharmaceuticalsNCT03827798Written as VAY736
- Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus NephritisActive, not recruitingPhase 3Novartis PharmaceuticalsNCT05126277Written as ianalumab s.c. q4w
- A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.Active, not recruitingPhase 3Novartis PharmaceuticalsNCT05985915Written as Ianalumab (VAY736)
- Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From IanalumabWithdrawnPhase 2Novartis PharmaceuticalsNCT07039422Written as Ianalumab
- Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune DiseaseActive, not recruitingPhase 2Novartis PharmaceuticalsNCT06293365Written as VAY736 1ml PFS
- Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)Active, not recruitingPhase 3Novartis PharmaceuticalsNCT05624749Written as ianalumab
- Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)Active, not recruitingPhase 3Novartis PharmaceuticalsNCT05639114Written as Ianalumab
- A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic SclerosisActive, not recruitingPhase 2Novartis PharmaceuticalsNCT06470048Written as Ianalumab
- A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic AnemiaActive, not recruitingPhase 3Novartis PharmaceuticalsNCT05648968Written as Ianalumab
- A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed SteroidsActive, not recruitingPhase 3Novartis PharmaceuticalsNCT05653219Written as Ianalumab
- Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's SyndromeCompletedPhase 3Novartis PharmaceuticalsNCT05350072Written as VAY736
- Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's SyndromeActive, not recruitingPhase 3Novartis PharmaceuticalsNCT05349214Written as VAY736
- Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)Active, not recruitingPhase 3Novartis PharmaceuticalsNCT05653349Written as Ianalumab
- Study the Efficacy and Safety of VAY736 and CFZ533 in SLE PatientsCompletedPhase 2Novartis PharmaceuticalsNCT03656562Written as VAY736
See all 33 studies that test ianalumab →
Given in every arm · 1 — ianalumab is usual care beside what is tested
Codes
What other systems call ianalumab · ClinicalTrials.gg INT001242
- MeSH (NLM) C000656267ianalumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) ZN2GQ3II96IANALUMABConfirmed FDA, NLM
- NCI Thesaurus C116788IanalumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000656267 | ianalumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | ZN2GQ3II96 | IANALUMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C116788 | Ianalumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.